Full Archive
PIPAC for Malignant Peritoneal Mesothelioma: Current Insights and Future Directions
Digestive Surgery 2026 May 12 [Link] Arianna Castagna, Aphrodite Fotiadou, Ali Ramouz, Preslava Gesheva, Niall Brindl, Wiebke Solass, Andreas Brandl Abstract Malignant peritoneal mesothelioma (MPM) is a rare and aggressive tumour with poor prognosis, often diagnosed late due to nonspecific symptoms. Current standard treatment involves systemic chemotherapy and cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy…
Read MoreDiagnostic Challenges in Pleural Mesothelioma
Cancers 2026 April 25 [Link] Moshe Lapidot, Martin Sattler Abstract Accurate diagnosis of PM and precise histologic subtyping are critical for optimal therapeutic decision-making, as treatment strategies-including chemotherapy, immunotherapy, or multimodality approaches-are largely subtype-dependent. Because of the several-decade latency between fiber inhalation and symptom onset, many cases are diagnosed at an advanced stage, when patients…
Read MoreDevelopment of Mesothelioma in Organ Transplant Recipients: A Comprehensive Study of 10 Cases
Archives of Pathology & Laboratory Medicine 2026 May 11 [Link] Huihua Li, Andre E Nel, Sergio Pina-Oviedo, John M Carney, Carolyn H Glass, Thomas A Sporn, Richard Attanoos, Aliya N Husain, Sonja Klebe, Beiyu Liu, Victor L Roggli, Elizabeth N Pavlisko Abstract Context.—: The development of malignancy after organ transplant has been well recognized as…
Read MorePrognostic Significance of Inflammatory, Cellular, and Tumor-Specific Biomarkers in Patients With Pleural and Peritoneal Mesothelioma
Clinical Lung Cancer 2026 June [Link] Keval Yerigeri, Manjistha Sengupta, Jingli Zhang, Jeevan Puthiamadathil, Raffit Hassan Abstract Background: Mesothelioma is an aggressive malignancy with poor outcomes, particularly when diagnosed at advanced stages. This study evaluated the prognostic value of tumor-specific biomarkers: soluble mesothelin-related peptide (SMRP), megakaryocyte potentiating factor (MPF) and CA125; inflammatory markers: C-reactive protein…
Read MoreImpact of a national mesothelioma network on outcomes including survival
Thorax 2026 May 8 [Link] Matthew Tate, Joshua Joseph Roche, Selina Tsim, Neil McGlinchey, Katie Ferguson, Phil Reid, Philip Short, Mahendran Chetty, Clinton Ali, Noelle O’Rourke, Carol MacGregor, Carolyn MacRae, Laura McNaughton, Rebecca Bloomfield, Tracey Petrie, Susan Smyth, Jennifer Latham, Lynne Hunter, Rocco Bilancia, Alan Kirk, Craig Dick, Fiona Roberts, Elaine MacDuff, Jill Slavin, Hemamalini…
Read MoreReal-world outcomes of multimodal treatment for pleural mesothelioma: A retrospective study in a high-volume integrated regional center
JTCVS Open 2026 January 30 [Link] Alison S Baskin, Keza Levine, Yun-Yi Hung, Elaine Liang, Kian C Banks, J Marie Suga, Jeffrey B Velotta Abstract Objective: To evaluate overall survival (OS) associated with multimodal treatment regimens, including pleurectomy/decortication (PD) and systemic therapy, in patients with clinical stage I-II epithelioid pleural mesothelioma (PM). Methods: We identified…
Read MoreBAP1 and USP1 cooperate to regulate FANCD2 stability and cell proliferation in mesothelioma cells
Cell Death & Disease 2026 May 2 [Link] Koya Suzuki, Shinichi Kiyonari, Jo Nishino, Miki Takahashi, Yuna Kato, Miki Amano, Anna Ogiso, Tomohiro Akashi, Tohru Maeda, Norio Kaneda, Takashi Miida, Yutaka Kondo, Kenji Kadomatsu, Mamoru Kato, Koji Aoyama, Hiroshi Murakami, Yoshitaka Sekido, Yuko Murakami-Tonami Abstract BRCA1-associated protein 1 (BAP1) is frequently inactivated in pleural mesothelioma…
Read MoreEpidermal growth factor receptor-targeted near-infrared photoimmunotherapy for malignant pleural mesothelioma
Lung Cancer 2026 July [Link] Miyu Kano, Aki Furusawa, Seiichiro Takao, Motofumi Suzuki, Makoto Kano, Hiroshi Yamamoto, Peter L Choyke, Hisataka Kobayashi Abstract Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer mostly associated with asbestos exposure. Effective treatments are limited, and the prognosis is extremely poor. Therefore, the development of novel therapeutic approaches is…
Read MoreCellular Plasticity in Malignant Transformation: Mesothelial Cells
Pathobiology 2026 April 29 [Link] Claire W Michael, Ben Davidson Abstract Background: Mesothelial proliferations range from reactive lesions to benign and malignant tumors, bearing witness to the plasticity of these cells. Their diagnosis often requires combination of morphological assessment, immunohistochemistry, and molecular testing. Summary: Considerable progress has been made in recent years in all the…
Read MoreCellular Plasticity in Malignant Transformation: Mesothelial Cells
Pathobiology 2026 April 29 [Link] Claire W Michael, Ben Davidson Abstract Background: Mesothelial proliferations range from reactive lesions to benign and malignant tumors, bearing witness to the plasticity of these cells. Their diagnosis often requires combination of morphological assessment, immunohistochemistry, and molecular testing. Summary: Considerable progress has been made in recent years in all the…
Read More
Skip to content